Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on July 12, 2018. The filing reports a corporate governance event: the promotion of David M. Urso, J.D., to Chief Operating Officer, effective immediately. Mr. Urso previously served as Senior Vice President of Corporate Development and General Counsel since March 2014.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
- Base Salary Increase: Mr. Urso's annual base salary increased to $426,000.
- Bonus Structure: Annual target bonus remains at 40% of the new base salary for the fiscal year ending June 30, 2019.
- Equity Grant: Mr. Urso received an award of 220,000 options to purchase common stock at an exercise price of $4.28. This includes 90,000 options for the promotion and 130,000 as annual compensation.
Material Changes
The primary material change is the amendment to Mr. Urso's Employment Agreement regarding termination compensation:
- Severance Cash: Increased from nine months to twelve months of annual base salary in the event of termination without Cause or resignation with Good Reason.
- Option Acceleration: The portion of options accelerated upon such termination increased from those vesting over nine months to those vesting over twelve months.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The only contingency noted is the specific definition of "Cause" and "Good Reason" within the Employment Agreement, which triggers the enhanced severance and acceleration terms described above.
Investor Verification Checklist
- Verify the exact terms of "Cause" and "Good Reason" in the amended Employment Agreement (Exhibit 10.1) to understand the triggers for the increased severance.
- Confirm the total number of outstanding options and the dilution impact of the 220,000 new options granted.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the promotion not detailed in the 8-K.
- Note that the registrant name in the metadata request ("Lite Strategy, Inc.") differs from the actual filing registrant ("MEI Pharma, Inc.").